Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Inovio Begins Phase I Trials of DNA Vaccine, Fast-Track Drug Dialogue Continues

Plus: European Liver Meeting Postponed, AACR Goes Virtual

Executive Summary

Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?

You may also be interested in...



Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold

The US FDA appears to have concerns about the device used to administer the vaccine.

Coronavirus Update: COVID-19 Funding Crisis For UK Medical Charities, Inovio Gets US Government Cash

UK medical research charities call for government assistance to temper damage caused by the pandemic, Inovio gets $71m in DOD contract to fund its vaccine, while ViralClear partners with Catalent to produce oral formulations of its antiviral merimepodib.

Coronavirus Sponsors Should Get Responses To Regulatory Requests Within One Day, US FDA Says

As part of the new Coronavirus Treatment Acceleration Program, FDA staff also are being reassigned to handle investigational therapy requests faster.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel